| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.21 | 6e-10 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.25 | 4e-07 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.8 | 2e-05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.15 | 7e-05 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.18 | 0.0002 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.18 | 0.0004 |